Involvement of Lymphatics in Lymphangioleiomyomatosis

Lymphatic Research and Biology

Volumn 7, Issue 4, 2009, Pages 221-228

  Glasgow, Connie G ^a   Taveira–dasilva, Angelo ^a   Pacheco–rodriguez, Gustavo ^a   Steagall, Wendy K ^a   Tsukada, Katsuya ^a   Cai, Xiong ^a   El–chemaly, Souheil ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN D;

ARTICLE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; HUMAN; LONGITUDINAL STUDY; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHANGIOLEIOMYOMATOSIS; MALE; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY;

CASE-CONTROL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LYMPHANGIOGENESIS; LYMPHANGIOLEIOMYOMATOSIS; LYMPHATIC VESSELS; MALE; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 77952317601     PISSN: 15396851     EISSN: 15578585     Source Type: Journal    
DOI: 10.1089/lrb.2009.0017     Document Type: Article

References (70)

1. Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: A report of patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995;151:527-533.
2. Chu S, Horiba K, Usuki J, Avila N, Chen C, Travis W, Ferrans V, Moss J. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999;115:1041-1052.
3. Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, Cordier J-F. Pulmonary lymphangioleiomyomatosis: A study of 69 patients. Medicine 1999;78:321-337.
4. Johnson S, Tattersfield A. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000;55:1052-1057.
5. Ryu J, Moss J, Beck G, Lee J-C, Brown K, Chapman J, Finlay G, Olson E, Ross S, Maurer J, Raffin T, Peavy H, McCarthy K, Taveira-DaSilva A, McCormack F, Avila N, DeCastro R, Jacobs S, Stylianou M, Fanburg B, for the NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: Characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006;173:105-111.
6. Johnson S, Whale C, Hubbard R, Lewis S, Tattersfield A. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004;59:800-803.
7. Taveira-DaSilva A, Steagall W.K., Moss J. Lymphangioleiomyomatosis. Cancer Control 2006;13:276-285.
8. Taveira-DaSilva A, Hedin C, Stylianou M, Travis W, Matsui K, Ferrans F, Moss J. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001;164:1072-1076.
9. Avila N, Chen C, Chu S, Wu M, Jones E, Neumann R, Moss J. Pulmonary lymphangioleiomyomatosis: Correlation of ventilaton-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 2000;214:441-446.
10. Taveira-DaSilva A, Stylianou M, Hedin C, Kristof A, Avila N, Rabel A, Travis W, Moss J. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2003;168:1427-1431.
11. Taveira-DaSilva A, Hathaway O, Sachdev V, Shizukuda Y, Birdsall C, Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: An echocardiographic study. Chest 2007;1332:1573-1578.
12. Taveira-DaSilva A, Stylianou M, Hedin C, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004;126:1867-1874.
13. Moss J, Avila N, Barnes P, Litzenberger R, Bechtle J, Brooks P, Hedin C, Hunsberger S, Kristof A. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001;163:669-671.
14. Franz D, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby T, Kwiatkowski D, McCormack F. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001;164:661-668.
15. Costello L, Hartman T, Ryu J. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000;75:591-594.
16. Osborne J, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann NY Acad Sci 1991;615:125-127.
17. Sampson J, Harris P. The molecular genetics of tuberous sclerosis. Hum Mol Genetics 1994;3:1477-1480.
18. Tee A, Fingar D, Manning B, Kwiatkowski D, Cantley L, Blenis J. Tuberous sclerosis complex-1 and Â2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 2002;99:13571-13576.
19. Tee A, Manning B, Roux P, Cantley L, Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003;13:1259-1268.
20. Goncharova E, Goncharov D, Eszterhas A, Hunter D, Glassberg M, Yeung R, Walker C, Noonan D, Kwiatkowski D, Chou M, Panettieri Jr. R, Krymskaya V. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM) J Biol Chem 2002;277:30958-30967.
21. Bissler J, McCormack F, Young L, Elwing J, Chuck G, Leonard J, Schmithorst V, Laor T, Brody A, Bean J, Salisbury S, Franz D. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-151.
22. McCormack F., Lymphangioleiomyomatosis: A clinical update. Chest 2008;133:507-516.
23. Smolarek T, Wessner L, McCormack F, Mylet J, Menon A, Henske E. Evidence that lymphangiomyomatosis is caused by TSC2 Mutations: Chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998;62:810-815.
24. Carsillo T, Astrinidis A, Henske E. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000;97:6085-6090.
25. Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S-i, Fukuchi Y, Hino O. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 2002;47:20-28.
26. Avila N, Dwyer A, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: Comparison of CT features. Radiology 2007;242:277-285.
27. Ferrans V, Yu Z-X, Nelson W, Valencia J, Tatsuguchi A, Avila N, Riemenschneider W, Matsui K, Travis W, Moss J. Lymphangioleiomyomatosis (LAM): A review of clinical and morphological features. J Nippon Med Sch 200;67:311-329.
28. Matsui K, Tatsuguchi A, Valencia J, Yu Z-X, Bechtle J, Beasley M, Avila N, Travis W, Moss J, Ferrans V. Extrapulmonary lymphangioleiomyomatosis (LAM): Clinicopathologic features in 22 cases. Hum Pathol 2000;31:1242-1248.
29. Maziak D, Kesten S, Rappaport D, Maurer J. Extrathoracic angiomyolipomas in lymphangioleimyomatosis. Eur Respir J 1996;9:402-405.
30. Kelly J, Moss J. Lymphangioleiomyomatosis. Am J Med Sci 2001;321:17-25.
31. Bissler J, Kingswood J. Renal angiomyolipomata. Kidney Int 2004;66:924-934.
32. Matsui K, Beasley M, Nelson W, Barnes P, Bechtle J, Falk R, Ferrans V, Moss J, Travis W. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 2001;29:1356-1366.
33. Taveira-DaSilva A, Steagall W.K., Rabel A, Hathaway O, Harari S, Cassandro R, Stylianou M, Moss J. Reversible airflow obstruction in lymphangioleiomyomatosis. Chest 2009 May 15. [Epub ahead of print] PMID: 19447921.
34. Matsui K, Riemenschneider W, Hilbert S, Yu Z-X, Takeda K, Travis W, Moss J, Ferrans V. Hyperplasia of type II pneumocytes in pulmonary lymphangioleimyomatosis: Immunohistochemical and electron microscopic study. Arch Pathol Lab Med 2000;124;1642-1648.
35. Matsumoto Y, Horiba K, Usuki J, Chu S, Ferrans V, Moss J. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 1999;21:327-336.
36. Inoue Y, King Jr T, Barker E, Daniloff E, Newman L. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med 2002;166:765-773.
37. Valencia J, Matsui K, Bondy C, Zhou J, Rasmussen A, Cullen K, Yu Z-X, Moss J, Ferrans V. Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis. 2001;49:421-433.
38. Valencia J, Pacheco-Rodriguez G, Carmona A, Xavier J, Bruneval P, Riemenschneider W, Ikeda Y, Yu Z-X, Ferrans V, Moss J. Tissue-specific rennin-angiotensin system in pulmonary lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006;35:40-47.
39. Bittmann I, Burkhard R, Amann G, Lãhrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: New insights into pathogenesis. Hum Pathol 2003;34:95-98.
40. Karbowniczek M, Astrinidis M, Balsara B, Testa J, Lium J, Colby T, McCormack F, Henske E. Recurrent lymphangiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-982.
41. Crooks D, Pacheco-Rodriguez G, deCastro R, McCoy Jr P, Wang J, Kumaki F, Darling T, Moss J. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleimyomatosis. Proc Natl Acad Sci USA 2004;101:17462-17467.
42. Pacheco-Rodriguez G, Steagall W.K., Crooks D, Stevens L, Hashimoto H, Li S, Wang J-A, Darling T, Moss J. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res 2007;67:10573-10581.
43. Li S, Takeuchi F, Wang J-A, Fuller C, Pacheco-Rodriguez G, Moss J, Darling T. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. JEM 2005;202:617-624.
44. Pacheco-Rodriguez G. Kumaki F, Steagall W.K., Zhang Y, Ikeda Y, Lin J-P, Billings E, Moss J.,- Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol. 2009;182:1270-1277.
45. Parks W, Shapiro S. Review; Matrix metalloproteinases in lung biology. Respir Res 2001;2:10-19.
46. Matsui K, Takeda K, Yu Z-X, Travis W, Moss J, Ferrans V. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleimyomatosis. Arch Pathol Lab Med 2000;124:267-275.
47. Hayashi T, Fleming M, Stetler-Stevenson W, Liotta L, Moss J, Ferrans V, Travis W. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 1997;28:1071-1078.
48. Zhe S, Yang Y, Jakkaraju S, Schuger L. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: Potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol 2003;28:504-511.
49. Krymskaya V, Shipley J. Lymphangioleiomyomatosis: Aa complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol 2003;28:546-550.
50. Steagall W.K., Glasgow C.G., Hathaway O, Avila N, Taveira-DaSilva A, Rabel A, Stylianou M, Lin J-P, Chen X, Moss J. Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 2007;293:L800-L808.
51. Avila N, Kelly J, Chu S, Dwyer A, Moss J. Lymphangioleiomyomatosis: Abdominopelvic CT and US findings. Radiology 2000;216:147-153.
52. Avila N, Bechtle J, Dwyer A, Ferrrans V, Moss J. Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. Radiology 2001;221:415-421.
53. Avila N, Dwyer A, Murphy-Johnson D, Brooks P, Moss J. Sonography of lymphangioleiomyoma in lymphangioleiomyomatosis: Demonstration of diurnal variation in lesion size. Am J Roentgenol 2005;184:459-464.
54. Webb D, Clarke A, Fryer A, Osborne J. The cutaneous features of tuberous sclerosis: A population study. Br J Dermatol 1996;135:1-5.
55. Nguyen-Vu P-A, Fackler I, Rust A, DeClue J, Sander C, Volkenandt M, Flaig M, Yeung R, Wienecke R. Loss of tuberin, the tuberous-sclerosis-complex-2 gene is associated with angiogenesis. J Cutan Pathol 2001;28:470-475.
56. Arbiser J, Brat D, Hunter S, D'Armiento J, Henske E, Arbiser Z, Bai X, Goldberg G, Cohen C, Weiss S. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol 2002;46:376-380.
57. Sanchez N, Wick M, Perry H. Adenoma sebaceum of Pringle: A clinicopathologic review, with a discussion of related pathologic entities. J Cutan Pathol 1981;8:395-403.
58. Wolff M. Lymphangiomyoma: Clinicopathologic study and ultrastructural confirmation of its histogenesis. Cancer 1973;31:988-1007.
59. Corrin B, Liebow A, Friedman P. Pulmonary lymphangiomyomatosis, a review. Am J Pathol 1975;79:348-368.
60. Basset F, Soler P, Marsac J, Corrin B. Pulmonary lymphangiomyomatosis: Three new cases studied with electron microscopy. Cancer 1976;38:2357-2366.
61. Stacker S, Baldwin M, Achen M. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 2002;16:922-934.
62. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol. Rev 2002;82:673-700.
63. Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T, Hayashi S, Minami M, Uekusa T, Fukuchi Y, Suda K. Lymphangiogenesis in lymphangioleiomyomatosis: Its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol 2004;289:1007-1016.
64. Itami M, Teshima S, Asakuma Y, Hino H, Aoyama K, Fukushima N. Pulmonary lymphangiomyomatosis diagnosed by effusion cytology. A case report. Acta Cytol 1997;41:522-528.
65. Yamauchi M, Nakahara H, Uyama K, Tsumjimoto A, Tamai M, Aozasa K. Cytologic finding of chyloascites in lymphangioleiomyomatosis. A case report. Acta Cytol 2000;44:1081-1084.
66. Kumasaka T, Seyama K, Mitani K, Souma S, Kashiwagi S, Hebisawa A, Sato T, Kubo H, Gomi K, Shibuya K, Fukuchi Y, Suda K. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 2005;29:13556-11366.
67. Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006;3:143-152.
68. Young L, Inoue Y, McCormack F. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008;358:199-200.
69. Glasgow C.G., Nilo A, Lin J-P, Stylianou M, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009;135:1293-1300.
70. Brugarolas J, Vazquez F, Reddy A, Sellers W, Kaelin Jr. W. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-158.